Strides Pharma Science said its flagship facility in Bangalore received the establishment inspection report from the US drug regulator.
Strides Pharma Science's flagship facility, KRS Gardens in Bangalore, Karnataka which was inspected by the United States Food & Drug Administration (USFDA) in March 2020, has received the Establishment Inspection Report (EIR), thereby confirming the successful closure of the inspections. The announcement was made before market hours today, 26 March 2020.
On a consolidated basis, the drug maker's net profit slumped 68% to Rs 93.89 crore despite a 28.5% rise in net sales to Rs 732.44 crore in Q3 December 2019 over Q3 December 2018.
Strides Pharma Science is a global pharmaceutical company. It focuses on difficult to manufacture products that are sold in over 100 countries.
The scrip was down 0.75% at Rs 317.25. It was trading in the range of Rs 312 to Rs 346.20 so far.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app